Target area | WHO 2020 targets (base year: 2015) | WHO 2030 targets (base year: 2015) | China 2020 targets |
Impact targets | |||
Incidence: new cases of chronic viral hepatitis B and C infections | 30% reduction (equivalent to 1% prevalence of HBsAg among children) | 90% reduction (equivalent to 0.1% prevalence of HBsAg among children) | Keeping <1% prevalence of HBsAg among children under 5 |
Mortality: viral hepatitis B and C deaths | 10% reduction | 65% reduction | No quantitative target |
Service coverage targets | |||
HBV vaccination: childhood third dose vaccination coverage | 90% | 90% | Keeping >95% |
Prevention of HBV mother-to-child transmission: HBV birth-dose vaccination coverage or other approaches to prevent mother-to-child transmission | 50% | 90% | Keeping >90% |
Blood safety | 95% of donations screened in a quality-assured manner | 100% of donations screened in a quality-assured manner | 100% of donations screened in a quality-assured manner |
Safe injections: percentage of injections administered with safety-engineered devices in and out of health facilities | 50% | 90% | No quantitative target |
Harm reduction: number of sterile needles and syringes provided per person who injects drugs per year | 200 | 300 | No quantitative target |
Viral hepatitis B and C diagnosis | 30% | 90% | No quantitative target |
Viral hepatitis B and C treatment | Globally 5 million people receiving HBV treatment and 3 million people receiving HCV treatment | 80% | No quantitative target |
China-specific service coverage targets | |||
Public awareness of viral hepatitis prevention and control knowledge | >50% | ||
Drug dependence treatment coverage to opioid users | >70% |
Sources: Global health sector strategy on viral hepatitis 2016–2021: towards ending viral hepatitis & Action plan for the prevention and treatment of viral hepatitis in China (2017–2020).
HBsAg, HBV surface antigen; HBV, Hepatitis B virus; HCV, hepatitis C virus.